Agreement with Framingham Pharma

 
TIDMRGT 
 
ReGen Signs Agreement with Framingham Pharma for the potential Distribution of 
its Nutraceutical ColostrininTM in Argentina, Uruguay and Paraguay 
 
15/12/2010 
 
ReGen Therapeutics Plc ('ReGen' or the 'Company) announces that it has today 
signed a Material Transfer Agreement (MTA) with Framingham Pharma of Argentina. 
 
Framingham is the leading marketer of dietary supplements in Argentina.  The 
second largest market in South America, which is a growth area of the world 
economy. Framingham reaches consumers across Argentina with a presence in all 
pharmacies. It promotes its products through direct contact with health 
professionals, participation in scientific events and significant media 
activity. Framingham is a prestigious laboratory recognized by both health 
professionals and the general public in Argentina. Framingham also has a 
significant distribution capability in Uruguay and Paraguay with local partners. 
Additional information is available on its corporate website 
www.framinghampharma.com 
 
 
Under the terms of this agreement ReGen will provide sufficient quantity of its 
proprietary nutraceutical ingredient Colostrinin(TM) to allow Framingham to 
develop a local formulation, initially for marketing in Argentina.  If 
successful this exercise will  lead to the signing of a formal Licensing and 
Distribution Agreement between the parties making Framingham the exclusive 
distributor of Colostrinin(TM) in Argentina and other markets in the region. 
 
No further details of the agreement will be disclosed at this time. 
 
To date Colostrinin(TM) is marketed as a nutritional supplement to 'support 
healthy brain aging and cognition in humans' in the US, Canada, Australia and 
Poland under the brand name CogniSure(TM) *, in Cyprus under the brand name 
Cognase(TM) **, in the UK under the brand name MemoryAid (TM) ***, in Turkey 
under the brand name Dyna(TM)  **** and in India under the brand name Cognate 
(TM)  ***** 
 
LG Life Sciences, Ltd ('LGLS') have also been appointed as the exclusive 
distributor of ColostrininTM in South Korea subject to import and regulatory 
approval being obtained******. 
 
Following on from India, Turkey and S Korea the ReGen Board is delighted that 
the Company has entered yet another growing market, which should lead to growth 
in sales higher than in the older developed world. 
 
 
 
 
 
*         Colostrinin(TM) for use as a human nutraceutical is licensed in North 
America and Australasia to Metagenics Inc. of San Clemente, California 
(www.metagenics.com). 
 
            Colostrinin(TM)  is distributed in Poland by Tagerr Polska,  an 
affliate of Tagerr a professional services and trading company  established in 
Köln, Germany. (www.cognisure.eu) 
 
**        Colostrinin(TM) is distributed in the Republic of Cyprus by Golgi 
Pharmaceuticals Ltd (www.healthybrainaging.com). 
 
***      Colostrinin(TM) is distributed in the UK by PRG Nutraceuticals Ltd 
(www.memoryaid.com) 
 
****    Colostrinin(TM) is distributed in Turkey by Eczacibasi Ilac Pazarlama 
A.S (www.eczacibasi.com) 
 
*****   Colostrinin(TM) is distributed in India by USV Ltd (www.usvindia.com ) 
 
****** LG Life Sciences, South Korea (www.lgls.co.kr) 
 
 
 
For further information: 
 
Percy Lomax 
ReGen Therapeutics Plc 
Tel No 020 7153 4920 
 
Roland Cornish/Felicity Geidt 
Beaumont Cornish Limited 
Tel No 020 7628 3396 
 
Nick Bealer/David Scott 
Alexander David 
Tel No 020 7448 9820 
 
 
 
 
 
 
 
 
 
 
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: ReGen Therapeutics Plc via Thomson Reuters ONE 
 
[HUG#1472690]